Summary of Structure Therapeutics Conference Call on Aleniglipron Company Overview - **Company**: Structure Therapeutics (NasdaqGM:GPCR) - **Product**: Aleniglipron, an oral small molecule GLP-1 receptor agonist Key Industry Insights - **Clinical Program**: ACCESS II clinical program for aleniglipron - **Market Context**: Addressing the global obesity pandemic, with an estimated 1 billion people living with obesity by 2030 Core Findings and Data - **Efficacy Results**: - ACCESS II study showed a placebo-adjusted mean weight loss of **15.3%** at doses of **180 mg** and **240 mg** after **36 weeks** [5][8] - At **44 weeks**, the mean weight loss was **16.3%** for **180 mg** and **16%** for **240 mg** with no signs of plateauing [8][29] - In the ACCESS open label extension, participants on **120 mg** experienced a body weight loss of up to **16.2%** after a median follow-up of **20 weeks** [7][29] - **Safety and Tolerability**: - Overall adverse event (AE)-related treatment discontinuation rate was **2%** in the ACCESS open label extension [9][22] - No events of drug-induced liver injury or QTc prolongation were reported across all studies [9][28] - The gastrointestinal tolerability profile improved with a starting dose of **2.5 mg**, showing a lower incidence of AEs compared to higher starting doses [9][26] - **Dosing Strategy**: - The strategy of starting low at **2.5 mg** and titrating slowly was emphasized as effective in optimizing tolerability while achieving weight loss [11][57] - Participants showed early signs of weight loss, achieving **6.4% to 6.8%** weight loss after a median follow-up of **20 weeks** when starting at **2.5 mg** [29] Additional Insights - **Future Studies**: Structure Therapeutics plans to share more data from four additional studies throughout **2026**, including type 2 diabetes and body composition studies [32] - **Regulatory Plans**: An end of phase 2 meeting with the FDA is scheduled for **Q2 2026**, with plans to initiate phase 3 in the second half of the year [32] - **Pipeline Expansion**: The company is developing an amylin program with two molecules, ACCG-2671 and ACCG-3535, to complement the GLP-1 program [33] Competitive Landscape - **Differentiation**: Aleniglipron is positioned as a potentially best-in-class oral GLP-1 with a strong safety profile, scalability, and combinability with other treatments [34][77] - **Market Need**: The company emphasizes the need for oral small molecules to meet the demand of over **100 million** people in the U.S. living with obesity [35] Conclusion - Structure Therapeutics presents compelling evidence for aleniglipron's efficacy and safety, positioning it as a significant player in the obesity treatment market. The ongoing studies and strategic plans indicate a strong commitment to addressing the global obesity crisis with innovative solutions.

Core Insights - The company reported significant weight loss results from its investigational oral drug, aleniglipron, designed for treating obesity, contributing to a rise in stock price while broader markets showed mixed movements [1] Group 1: Clinical Trial Results - Aleniglipron achieved a placebo-adjusted mean weight loss of 16.3% (39 lbs) at the 180 mg dose and 16.0% (37 lbs) at the 240 mg dose after 44 weeks, with no evidence of a weight loss plateau [2] - Interim data from the ongoing ACCESS Open Label Extension study showed continued weight loss of up to 16.2% (40.5 lbs) with the 120 mg dose at 56 weeks, demonstrating the drug's efficacy and favorable safety profile [2][3] Group 2: Regulatory and Development Plans - The company plans to hold an FDA end-of-Phase 2 meeting in Q2 2026, with Phase 3 initiation on track for the second half of 2026 [4] - The trial is designed with a starting titration dose of 2.5 mg, intending to evaluate multiple doses up to 240 mg [4] Group 3: Competitive Advantages - CEO Raymond Stevens highlighted four factors that could make aleniglipron competitive, including its efficacy, with a higher dose leading to weight loss of up to 15.3% at 36 weeks [5] - The drug's manufacturing cost is favorable as a small-molecule pill, allowing for efficient production at scale for the U.S. market [6] - Aleniglipron can be combined with other therapies, showing synergistic effects when paired with an amylin-targeting drug [6] Group 4: Stock Performance and Technical Indicators - The stock is currently trading 6.5% below its 20-day simple moving average (SMA) but 1.3% above its 100-day SMA, indicating short-term weakness while maintaining longer-term strength [7] - Over the past 12 months, shares have increased by 146.67%, positioned closer to their 52-week highs than lows [7] Group 5: Analyst Consensus and Market Position - The stock carries a Buy Rating with an average price target of $101.20, indicating positive analyst sentiment [9] - Recent analyst actions include a Buy rating from HC Wainwright & Co. with a target raised to $114.00 [10]

Core Viewpoint - The relationship between pharmaceutical giant Novo Nordisk and telehealth company Hims & Hers Health has evolved from collaboration to legal disputes, but a new agreement allows Hims & Hers to sell Novo Nordisk's GLP-1 drugs, which could benefit both companies and their investors [1][2]. Group 1: Agreement Details - Hims & Hers Health will now sell FDA-approved GLP-1 drugs, Ozempic and Wegovy, including the newly approved Wegovy pill, improving its market position [5]. - Previously, Hims & Hers was selling compounded versions of these drugs, which were not FDA-approved, posing a risk to its growth potential amid increasing demand for GLP-1 drugs [5]. Group 2: Company Performance - Novo Nordisk has reduced its sales guidance for the upcoming year due to competition, particularly from Eli Lilly's GLP-1 treatments and the trend of patients opting for compounded versions to save costs [6]. - The new agreement with Hims & Hers Health could enhance Novo Nordisk's growth rate moving forward [6]. Group 3: Stock Performance - Both Novo Nordisk and Hims & Hers Health have seen their stock prices decline over 20% this year, with Hims & Hers experiencing more volatility, including a drop of up to 55% at one point [7]. - Novo Nordisk, valued at nearly $170 billion, is considered a safer investment compared to Hims & Hers, which has a market cap of around $6 billion and lighter margins [7][8].

Summary of Nasus Pharma Conference Call Company Overview - **Company**: Nasus Pharma - **Product**: NS002, an intranasal powder epinephrine product candidate designed to treat anaphylaxis - **Technology**: Proprietary powder technology called Nasax, which enhances drug absorption compared to traditional liquid formulations [2][3] Industry Context - **Current Standard of Care**: Epinephrine intramuscular auto-injectors (e.g., EpiPen) are commonly used for anaphylaxis treatment, but many patients do not carry them due to needle phobia and device bulkiness [4] - **Market Research Insights**: 90% of allergists prioritize speed of onset when prescribing epinephrine products, with 87% considering T100 (time to therapeutic threshold) clinically meaningful [4][5] Key Findings from Phase 2 Study - **Study Design**: Involved 50 healthy adults with allergic rhinitis, assessing NS002 under normal conditions and nasal congestion [6] - **Pharmacokinetic Results**: - NS002 achieved T100 in a median of 1.69 minutes compared to 3.42 minutes for EpiPen, indicating a statistically significant improvement [9][12] - At 2.5 minutes, 67% of NS002 subjects reached the therapeutic threshold versus 27% for EpiPen; at 5 minutes, 88% for NS002 versus 64% for EpiPen [10][12] - NS002 demonstrated 60% higher total epinephrine absorption in the critical 10-minute window compared to EpiPen [13] - **Safety Profile**: NS002 was well-tolerated with no serious adverse events reported; most adverse events were mild and self-resolving [11][13] Competitive Advantages - **Speed of Onset**: NS002's rapid absorption is crucial for emergency situations, potentially reducing the need for repeat doses [8][11] - **Device Design**: NS002 is a compact, needle-free device that is easy to carry, enhancing patient convenience and compliance [4][54] - **Shelf Life**: The dry powder formulation offers enhanced stability and longer shelf life compared to liquid formulations [54] Future Development Plans - **Pivotal Study**: Planned for initiation in Q4 2026, with top-line data expected by Q1 2027; will include comparisons to EpiPen and intramuscular adrenaline [15][39][56] - **Regulatory Strategy**: The company aims to submit an NDA in the second half of 2027, focusing on demonstrating comparability to EpiPen for FDA approval [39][48] Market Potential - **Physician Acceptance**: There is openness among allergists to switch patients to needle-free options, indicating potential market uptake for NS002 [18] - **Best-in-Class Potential**: The company believes NS002 could be a best-in-class treatment based on its pharmacokinetic profile and performance compared to existing products [23][24] Additional Considerations - **Publication Plans**: The company intends to publish study data in a peer-reviewed journal and present at major allergy conferences [30][31] - **Comparative Analysis**: While comparisons to other products like Neffy were discussed, the focus remains on NS002's superior profile based on available data [37] This summary encapsulates the critical insights and developments discussed during the conference call, highlighting the potential of Nasus Pharma's NS002 in the anaphylaxis treatment landscape.

Core Insights - Artisan Value Fund outperformed the Russell 1000® Value Index in Q4 2025, returning 4.60% compared to the Index's 3.81% [1] - For the full year 2025, the Fund returned 14.28% versus 15.91% for the Index, demonstrating effective investment discipline over three, five, and ten years [1] Company Highlights - Merck & Co., Inc. (NYSE:MRK) was a leading contributor to the Fund's performance, with shares returning over 20% in Q4 2025 [2][3] - As of March 13, 2026, Merck's stock closed at $115.61, with a one-month return of -5.48% and a 52-week gain of 21.07% [2] - Merck has a market capitalization of $285.833 billion [2] Investment Sentiment - Despite recent setbacks with the Gardasil vaccine, Merck's late-stage pipeline holds significant potential, with multiple programs in clinical development [3] - The market has been skeptical about Merck's innovation capabilities, particularly with concerns over the upcoming patent expiration of its oncology drug Keytruda in 2028 [3] - Merck's strong balance sheet and robust free cash flow provide opportunities for future partnerships, acquisitions, and capital returns to shareholders [3]

Fourth Quarter and Seven-Month Transition Period Ending December 31, 2025 Results March 16, 2026 Fiscal Year Change On August 1, 2025, our Board of Directors approved a change in the Company's fiscal year that ended on the last Sunday of May to a fiscal year that corresponds with the calendar year, ending on December 31st, effective for the fiscal period beginning May 26, 2025, and ending December 31, 2025 (the "Fiscal Year Change"). The Fiscal Year Change is applied on a prospective basis and does not adju ...

Core Viewpoint - A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated, alleging that the company made materially false and misleading statements regarding its drug relacorilant during the class period from October 31, 2024, to December 30, 2025 [1][2]. Group 1: Allegations Against Corcept - Defendants allegedly overstated the strength of clinical trials supporting relacorilant, misrepresenting them as "powerful support" for the New Drug Application (NDA) to the FDA [2]. - The complaint claims that defendants falsely conveyed confidence in relacorilant's regulatory prospects, stating they had communicated with the FDA and anticipated no impediments to approval, despite the FDA raising concerns about the adequacy of clinical evidence [2]. - As a result of these actions, defendants failed to disclose the material risk that Corcept's relacorilant NDA might not be approved, making their statements about the company's business and prospects misleading [2]. Group 2: Investor Information - Investors who suffered losses related to Corcept's securities have until April 21, 2026, to seek appointment as lead plaintiff in the class action lawsuit [3].

Core Insights - Fennec Pharmaceuticals has reached a settlement with Cipla regarding the litigation over Cipla's application to market a generic version of PEDMARK, with Cipla agreeing not to enter the market until September 1, 2033, or earlier under specific conditions [1] Company Overview - Fennec Pharmaceuticals is a specialty pharmaceutical company focused on reducing ototoxicity in cancer patients undergoing cisplatin-based chemotherapy [14] - PEDMARK is the first FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients aged 1 month and older with localized, non-metastatic solid tumors [2][6] Product Details - PEDMARK is a unique formulation of sodium thiosulfate available in single-dose, ready-to-use vials for intravenous use [2] - The product has been endorsed by the National Comprehensive Cancer Network (NCCN) for the adolescent and young adult population with a 2A recommendation [3] Market Context - Approximately 500,000 patients in the U.S. are diagnosed annually with cancers treatable by platinum-based chemotherapy, with many experiencing lifelong hearing loss due to ototoxicity [4] - Prior to PEDMARK's FDA approval, there were no preventative agents for hearing loss resulting from cancer treatment, significantly impacting patients' quality of life [4] Clinical Studies - PEDMARK has been validated through two Phase 3 clinical studies, COG ACCL0431 and SIOPEL 6, demonstrating its efficacy in reducing ototoxicity [5] - The COG ACCL0431 study included various childhood cancers treated with intensive cisplatin therapy, while SIOPEL 6 focused on hepatoblastoma patients [5] Regulatory and Commercialization Status - PEDMARK received FDA approval in September 2022 and has also been approved in Europe and the U.K. under the brand name PEDMARQSI [14][15] - Fennec has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the U.K., Australia, and New Zealand [15] - The product has Orphan Drug Exclusivity in the U.S. and Pediatric Use Marketing Authorization in Europe, providing significant market protection [16]

Core Insights - Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete, with topline data expected in Q3 2026 [1] - Enrollment in the psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) sub-studies of SKYWAY is on track, with topline readouts anticipated in Q4 2026 [1] - The SKYLINE platform trial in ulcerative colitis (UC) is enrolling ahead of schedule, with Part A readouts starting in Q2 2026 [1] Company Overview - Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases [5] - The company's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23 [5] Product Insights - SPY072 is an investigational antibody targeting TL1A, designed for superior potency and convenience, potentially allowing for quarterly or biannual subcutaneous maintenance dosing [4] - The SKYWAY Phase 2 trial is a randomized and placebo-controlled study evaluating SPY072 in patients with moderately to severely active RA, PsA, or axSpA [3]

Industry Overview - The GLP-1 agonist market is projected to reach nearly $63 billion by early 2026, with forecasts indicating it could triple over the next decade [2] - The biopharma industry is rapidly developing new GLP-1 receptor agonist medications, with numerous firms involved in this growth [3] Company Focus: Eli Lilly - Eli Lilly and Company is a major player in the pharmaceutical industry, with a market capitalization nearing $1 trillion and shares increasing by almost 20% in the past year [4] - The company plans to invest $3 billion in China over the next decade to enhance its supply chain and local manufacturing capacity for GLP-1 medications, aiming to tap into the growing weight-loss market [5] - Eli Lilly has filed for approval of a new GLP-1 treatment, orforglipron, for obesity in the U.S. and over three dozen other countries, with a domestic launch expected by mid-2026 [6] Competitive Landscape - Eli Lilly's size and market position enable it to develop multiple GLP-1 medicines and expand globally [7] - Other companies to watch in the GLP-1 space include Viking Therapeutics and Structure Therapeutics, which are smaller but have promising GLP-1 candidates in clinical trials [7]